Main Article Content
Asthma, COVID-19, Cross-sectional study, Children, Adult
Background: It has recently been argued that asthma does not increase the risk of severe acute respiratory syndrome coronavirus-2 (SARS-CoV-2) infection. If so, the prevalence of asthma in subjects diagnosed with COVID-19 should be lower than in the general population.
Objective: To determine the prevalence of asthma in Mexican children and adults with SARS-CoV-2 infection.
Methods: A public database of the Epidemiological Surveillance System for Viral Respiratory Disease in Mexico was analyzed. Those who underwent the real-time reverse transcriptase-polymerase chain reaction-SARS-CoV-2 (rtRT-PCR-SARS-CoV-2) test from February 27 to June 21, 2020, were included. In addition to the prevalence of asthma, some factors associated with it were investigated.
Results: Data from 417,366 subjects were analyzed. Asthma prevalence in children, adults, and global were 3.7%, 3.3%, and 3.3%, respectively. Although the asthma prevalence was lower in SARS-CoV-2 positive over negative patients, significant differences were only found in adults (2.8% vs. 3.7% respectively; odds ratio (OR) = 0.74; 95% confidence interval (CI): 0.71–0.77); but not in children (3.5% vs. 3.8%, respectively; OR = 0.91; 95%CI: 0.76–1.10). Multivariate analysis showed in younger than 18 years that girls and immunosuppression were factors associated with a decrease in the odds to develop asthma. In adults, asthma was positively associated with females, obesity, smoking, immunosuppression, chronic obstructive pulmonary disease, arterial hypertension, and cardiovascular disease.
2. Lai CK, Beasley R, Crane J, Foliaki S, Shah J, Weiland S, et al. Global variation in the prevalence and severity of asthma symptoms: Phase three of the International Study of Asthma and Allergies in Childhood (ISAAC). Thorax. 2009;64:476–83. https://doi.org/10.1136/thx.2008.106609
3. To T, Stanojevic S, Moores G, Gershon AS, Bateman ED, Cruz AA, et al. Global asthma prevalence in adults: Findings from the cross-sectional world health survey. BMC Public Health. 2012;12:204. https://doi.org/10.1186/1471-2458-12-204
4. Al Huraimel K, Alhosani M, Kunhabdulla S, Stietiya MH. SARS-CoV-2 in the environment: Modes of transmission, early detection and potential role of pollutions. Sci Total Environ. 2020;744:140946. https://doi.org/10.1016/j.scitotenv. 2020.140946
5. Novak N, Cabanillas B. Viruses and asthma: The role of com-mon respiratory viruses in asthma and its potential meaning for SARS-CoV-2. Immunology. 2020;161(2):83–93. https://doi. org/10.1111/imm.13240
6. Epidemiology Working Group for NCIP Epidemic Response, Chinese Center for Disease Control and Prevention. [The epidemiological characteristics of an outbreak of 2019 novel coronavirus diseases (COVID-19) — China, 2020]. Zhonghua Liu Xing Bing Xue Za Zhi. 2020; 41(2):113–22. Chinese. https://doi. org/10.3760/cma.j.issn.0254-6450.2020.02.003.
7. Li X, Xu S, Yu M, et al. Risk factors for severity and mortality in adult COVID-19 inpatients in Wuhan. J Allergy Clin Immunol. 2020;146:110–18. https://doi.org/10.1016/j.jaci.2020.04.006
8. Mancilla-Hernández E, González-Solórzano EVM, Medina-Ávalos MÁ, Barnica- Alvarado RH. Prevalencia de asma y sus síntomas en población escolar de Cuernavaca, Morelos, México [Prevalence of asthma and its symptoms in school-children from Cuernavaca, Morelos, Mexico]. Rev Alerg Mex. 2016;63:351–57. Spanish. https://doi.org/10.29262/ram. v63i4.189
9. Bedolla-Barajas M, Javier Ramírez-Cervantes F, Morales-Romero J, Jesús Pérez-Molina J, Meza-López C, Delgado-Figueroa N. A rural environment does not protect against asthma or other allergic diseases amongst Mexican chil-dren. Allergol Immunopathol. 2018;46:31–38. https://doi. org/10.1016/j.aller.2017.01.010
10. Morales-Romero J, Bedolla-Barajas M, López-Cota GA, Bedolla-Pulido TI, Bedolla-Pulido TR, Navarro-Lozano E, et al. Tendencia de la prevalencia de asma y sus síntomas en los adolescentes tardíos mexicanos en un periodo de siete años [Trends in the prevalence of asthma and its symptoms in Mexican late adolescents over a 7-year period]. Rev Alerg Mex. 2018;65:331–40. Spanish. https://doi.org/10.29262/ram. v65i4.392
11. Del-Rio-Navarro BE, Navarrete-Rodríguez EM, Berber A, Reyes-Noriega N, García-Marcos Álvarez L; et al. The burden of asthma in an inner-city area: A historical review 10 years after Isaac. World Allergy Organ J. 2020;13:100092. https:// doi.org/10.1016/j.waojou.2019.100092
12. García-Sancho C, Fernández-Plata R, Martínez-Briseño D, Franco-Marina F, Pérez-Padilla JR. Prevalencia y riesgos aso-ciados con pacientes adultos con asma de 40 años o más de la Ciudad de México: Estudio de base poblacional [Prevalence and risks associated with adult patients with asthma aged 40 years or more from Mexico City: A population-based study]. Salud Publica Mex. 2012;54:425–32. Spanish. https://doi. org/10.1590/s0036-36342012000400013
13. Bedolla-Barajas M, Valdez-López F, Alcalá-Padilla G, Bedolla-Pulido TI, Rivera-Mejia V, Morales-Romero J. Prevalence and factors associated to peanut allergy in Mexican school children. Allergol Immunopathol. 2017;45:69–76. https://doi.org/10. 1016/j.aller.2016.04.013
14. Bedolla-Barajas M, Macriz-Romero N, Jara-Ettinger AC, Macriz-Romero M, Fregoso-Fregoso M, Morales-Romero J. Autorreporte de alergia al látex en estudiantes de medicina: Prevalencia y factores asociados [Self-report of latex allergy in medical students: Prevalence and associated factors]. Rev Alerg Mex. 2018;65:10–18. Spanish. https://doi.org/10.29262/ ram.v65i1.290
15. Halpin DMG, Faner R, Sibila O, Badia JR, Agusti A. Do chronic respiratory diseases or their treatment affect the risk of SARS-CoV-2 infection? Lancet Respir Med. 2020;8:436–8. https://doi. org/10.1016/S2213-2600(20)30167-3
16. Zhu Z, Hasegawa K, Ma B, Fujiogi M, Camargo CA Jr, Liang L. Association of asthma and its genetic predisposition with the risk of severe COVID-19. J Allergy Clin Immunol. 2020;46(2):327-9.e4.. https://doi.org/10.1016/j.jaci. 2020.06.001
17. Jackson DJ, Busse WW, Bacharier LB, Kattan M, O’Connor GT, Wood RA, et al. Association of respiratory allergy, asthma, and expression of the SARS-CoV-2 receptor ACE2. J Allergy Clin Immunol. 2020;146:203–206.e3. https://doi.org/10.1016/j. jaci.2020.04.009
18. Abiad HF, Alameddine VM, Hallit S, Torbey P-H, Mroueh S, Yazbek N, et al. Aeroallergen sensitization in Lebanese asthmatic children: the results of a cohort national study. Environ Sci Pollut Res Int. 2020;27:5597–605. https://doi.org/10.1007/ s11356-019-07234-z
19. Kwizera R, Wadda V, Mugenyi L, Aanyu-Tukamuhebwa H, Nyale G, Yimer G, et al. Skin prick reactivity among asthmatics in East Africa. World Allergy Organ J. 2020;13:100130. https://doi.org/10.1016/j.waojou.2020.100130
20. Zhang J-J, Dong X, Cao Y-Y, Yuan Y-D, Yang Y-B, Yan Y-Q, et al. Clinical characteristics of 140 patients infected with SARS-CoV-2 in Wuhan, China. Allergy. 2020;75:1730–41. https://doi.org/10.1111/all.14238
21. Green I, Merzon E, Vinker S, Golan-Cohen A, Magen E. COVID-19 susceptibility in bronchial asthma. J Allergy Clin Immunol Pract. 2021; 9(2):684–92. . https://doi.org/10.1016/j. jaip.2020.11.020.
22. Grandbastien M, Piotin A, Godet J, Abessolo-Amougou I, Ederlé C, Enache I, et al. SARS-CoV-2 Pneumonia in Hospitalized Asthmatic Patients Did Not Induce Severe Exacerbation. J Allergy Clin Immunol Pract. 2020;8:2600-7. https://doi.org/10.1016/j.jaip.2020.06.032.
23. Chhiba KD, Patel GB, Vu THT, Chen MM, Guo A, Kudlaty E, et al. Prevalence and characterization of asthma in hospitalized and nonhospitalized patients with COVID-19. J Allergy Clin Immunol. 2020;146:307–314.e4. https://doi.org/10.1016/j. jaci.2020.06.010.
24. Lieberman-Cribbin W, Rapp J, Alpert N, Tuminello S, Taioli E. The impact of asthma on mortality in patients with COVID-19. Chest. 2020; 158(6): 2290–1. https://doi.org/10.1016/j. chest.2020.05.575.